EGFR and colorectal carcinoma: Both, ATM and TP53 are frequently mutated in cancers of the colon and rectum [12], but their predictive value for RAS wildtype CRC patients treated by EGFR-targeted therapy in combination with chemotherapy still has to be elucidated.